PRKCI and renal cell carcinoma: We reported that in RCC, inhibiting PKC-ι with combination treatment and siRNA knockdown resulted in a considerable reduction of the phospho-Akt and phospho-ERK1/2 levels in both cell lines, thereby negatively impacting the stability of c-Myc (Figures 6A, B).